Company Announces 2024 Strategic Priorities Focused on Advancement of Lomecel-B™ in Hypoplastic Left Heart Syndrome ELPIS II Phase 2 Trial of Lomecel-B™ in HLHS Continues Enrollment; Completion of Study Enrollment Anticipated in 2024 Long-term Survival Data from ELPIS 1 Trial Presented at the 2023 Scientific Sessions of the American Heart Association Announced Additional Validating Clinical Data […]

AUSTIN, Texas, Feb. 28, 2024 (GLOBE NEWSWIRE) — Volcon Inc. (NASDAQ: VLCN) (“Volcon” or the “Company”). Dear Volcon Customers, Dealers, Suppliers, and Investors, It’s been a little over three weeks since I took the role of CEO for Volcon Inc. I’d like to spend a moment to give you an update on the Company as […]

VIRGINIA BEACH, VA / ACCESSWIRE / February 28, 2024 / Millennials and their “fur babies” are taking center stage in modern society. As millennials are increasingly delaying major life milestones like marriage, children and home buying, pets seem to be the exception. As of 2024, 66% of American households own a pet, and more than half of […]

Woburn, Massachusetts–(Newsfile Corp. – February 27, 2024) – SinglePoint Inc (CBOE: SING) (“SinglePoint” or “the Company”) subsidiary Boston Solar, a proud partner of the Boston Red Sox and a leading provider of solar energy solutions, is entering into a contract with a leading American hotel chain. The proposed solar panel system is expected to be […]

NEW YORK, NY / ACCESSWIRE / February 26, 2024 / 1847 Holdings LLC (“1847” or the “Company”) (NYSE American:EFSH), a unique holding company that combines the attractive attributes of owning private, lower-middle market businesses with the liquidity and transparency of a publicly traded company, announced today that its subsidiary 1847 Cabinets Inc., a designer, manufacturer and […]

TEL AVIV, Israel, Feb. 27, 2024 (GLOBE NEWSWIRE) — SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders and rare diseases of the central nervous system, announced today that as part of its ongoing collaboration with Clearmind Medicine Inc. (“Clearmind”) (Nasdaq: CMND) (CSE: […]

Preliminary revenue for the first three months of fiscal year 2024 is approximately equal to revenue for the first six months of fiscal year 2023 Committed to continually improve operations and cost structure, combined with a focus on product optimization and innovative commercial strategies that leverage the growth potential of the product portfolio, to expand margins, […]

The initial purchase order is expected to generate more than $7 million of net revenue and TRNR has sufficient inventory to fulfill the entire purchase order The Company confirms that it expects to generate net revenue of between $15 million and $20 million in 2024 AUSTIN, TX – (NewMediaWire) – February 26, 2024 – Interactive […]

Targeted enrollment of 54 patients completed ahead of schedule SAN DIEGO, Feb. 26, 2024 (GLOBE NEWSWIRE) — Skye Bioscience, Inc. (OTCQB: SKYE) (“Skye” or the “Company”), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel classes of therapeutic drugs that modulate the endocannabinoid system, with an emphasis on obesity and ocular indications, […]